Please use this identifier to cite or link to this item:
Title: Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.
Austin Authors: Lee, S T;Ghanem, M;Herbertson, R A;Berlangieri, Salvatore U ;Byrne, Amanda J;Tabone, K;Mitchell, Paul L R ;Knight, Simon R ;Feigen, Malcolm;Scott, Andrew M 
Affiliation: Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 28-Mar-2009
Publication information: Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging 2009; 11(6): 473-9
Abstract: To evaluate prognostic value of integrated 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography/computed tomography (FDG-PET/CT) and correlate histopathological subtype with maximum standardized uptake value (SUV(max)) and survival in patients with malignant mesothelioma (MM).Retrospective review of FDG-PET/CT scans, with derivation of SUV(max) of FDG-avid lesions, was performed in patients with biopsy-proven MM. Clinical follow-up and Kaplan-Meier survival analysis was performed.Forty-six patients (37 M:9 F; mean age 61 years) with MM had a FDG-PET/CT scan in a 30-month period. Follow-up was available on 44/46 (96%) patients. Metastatic disease was detected in 9/46 (20%) patients on FDG-PET/CT, where 8/9 were previously undetected. Better survival was found in patients without metastases (p value < 0.05). Mean SUV(max) of primary pleural lesions in patients with metastatic disease was significantly higher than in patients without metastatic disease (p value < 0.05). Progression-free survival was significantly better in the epithelioid histology group compared to the biphasic group (p value 0.015).Detection of extrathoracic metastases on FDG-PET/CT and nonepithelioid histopathology are poor prognostic indicators in patients with MM.
Gov't Doc #: 19330385
DOI: 10.1007/s11307-009-0203-6
Journal: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Type: Journal Article
Subjects: Adult
Aged, 80 and over
Disease-Free Survival
Fluorodeoxyglucose F18.diagnostic use.metabolism
Follow-Up Studies
Kaplan-Meier Estimate
Mesothelioma.pathology.radiography.radionuclide imaging
Middle Aged
Pleural Neoplasms.pathology.radiography.radionuclide imaging
Positron-Emission Tomography.methods
Radiopharmaceuticals.diagnostic use.metabolism
Time Factors
Tomography, Emission-Computed.methods
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
19330385.pdf55.68 kBAdobe PDFView/Open
Show full item record

Page view(s)

checked on May 25, 2024


checked on May 25, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.